Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

Brain morphological changes associated with cyclic menstrual pain

Primary dysmenorrhea, or menstrual cramps, is the most common gynecological disorder in women of childbearing age. Lower abdominal pain starts with the onset of menstrual flow and this ongoing pain stimulus can cause alterations throughout the nervous system. In a study scheduled for publication in the September issue of PAIN, researchers report abnormal changes in the structure of the brain in PDM patients, whether or not they are in fact experiencing pain.

11 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

Ironwood provides investor update for second-quarter 2010

Ironwood Pharmaceuticals, Inc. today provided an update on its business activities for the second quarter of 2010.

7 Aug 2010

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has issued a positive opinion for RELISTOR (methylnaltrexone bromide) subcutaneous injection in pre-filled syringes.

7 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Researchers discover manipulation of microRNA-29a shows potential of novel IBS treatment

A possible cause of irritable bowel syndrome has been traced to a small piece of RNA that blocks a substance protecting the colon membrane, leading to hostile conditions that can produce diarrhea, bloating and chronic abdominal pain.New research shows that this RNA segment sends signals that stop the activity of the gene that produces glutamine, an amino acid. Previous research has linked a shortage of glutamine in the gut with the seepage of toxins and bacteria through the intestinal wall, irritating nerves and creating disease symptoms.

3 Aug 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.

28 Jul 2010

Obesity linked to rising womb cancer in women: Report

According to a new report from the Charity Cancer Research (CCR) in Britain, the number of women with womb cancer or uterine cancer is on the rise and obesity may be a clue to such rise.

26 Jul 2010

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

New data were presented today at the 18th International AIDS Conference from the VERxVE study that show an investigational, once-daily extended-release (400 mg QD) formulation of nevirapine was non-inferior to twice-daily immediate release Viramune® (nevirapine) tablets (200 mg BID), both in combination with Truvada® (tenofovir and emtricitabine) tablets in treatment-naive HIV-1 infected patients through 48 weeks.

23 Jul 2010

Womb cancer is the fourth most common cancer among UK women: Research

Womb cancer cases are highest ever for over three decades.The number of women diagnosed with womb cancer is at its highest for over 30 years according to new figures published today by Cancer Research UK which show more than 7,530 people now develop the disease each year in the UK.

22 Jul 2010

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

First-of-its-kind patient, healthcare provider support program for management of HE

Concentric Pharma Advertising, an independent healthcare advertising and marketing agency, announces the creation of Salix Pharmaceuticals' Hepatic Encephalopathy Living Program. H.E.L.P. launched May 24, 2010, and coincides with the launch of Xifaxan550 (rifaximin) for the management of patients 18 or older at risk for overt hepatic encephalopathy recurrence.

16 Jul 2010

Spanish scientists develop new parasite detection method to prevent Anisakidosis

A new method enables anisakids to be detected in any fish product, from a whole fish, fresh or frozen, to tinned fish and surimi. Developed by Spanish scientists, the system is based on molecular techniques and overcomes the limitations of traditional procedures.

16 Jul 2010

NIH announces 5 more years of funding for Consortium of Food Allergy Research

Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).

15 Jul 2010

Polyethylene glycol "works a bit better" than lactulose for chronic constipation: Study

When ordinary over-the-counter laxatives fail to work, doctors turn to other medications to treat people with constipation. Now, a new review of existing research finds that one common drug treatment is better than another is at helping patients who are desperate to get things moving.

7 Jul 2010

Abdominal Pain News and Research

Further Reading

Tamir Biotechnology's three compounds effective show potential for yellow fever

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Brain morphological changes associated with cyclic menstrual pain

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Progenics second-quarter total revenue decreases to $2.3 million

Ironwood provides investor update for second-quarter 2010

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Researchers discover manipulation of microRNA-29a shows potential of novel IBS treatment

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Obesity linked to rising womb cancer in women: Report

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

Womb cancer is the fourth most common cancer among UK women: Research

Genentech disappointed with FDA ODAC's recommendation against Avastin

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

First-of-its-kind patient, healthcare provider support program for management of HE

Spanish scientists develop new parasite detection method to prevent Anisakidosis

NIH announces 5 more years of funding for Consortium of Food Allergy Research

Polyethylene glycol "works a bit better" than lactulose for chronic constipation: Study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News